How Investors May Respond To Mirum Pharmaceuticals (MIRM) Gaining TimesSquare Backing And Expanding Livmarli’s Scope

• In the third quarter of 2025, TimesSquare Capital Management added Mirum Pharmaceuticals to its U.S. Small Cap Growth Strategy, while Mirum advanced plans to expand its lead liver disease drug, Livmarli, into a third treatment indication.
• This combination of increased institutional backing and a broader clinical scope for Livmarli highlights how financial and clinical momentum can reinforce each other for Mirum.
• Next, we’ll examine how Mirum’s inclusion in TimesSquare’s growth strategy could influence its existing investment narrative and future expectations.

We've found 11 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Mirum Pharmaceuticals Investment Narrative Recap

To own Mirum, you need to believe that a focused rare‑disease portfolio anchored by Livmarli can support durable revenue while new indications steadily reduce that dependence. TimesSquare’s small cap growth allocation and Mirum’s plan to extend Livmarli into a third indication reinforce the current growth story but do not change the key near term catalyst, which remains pivotal readouts from the Volixibat program, or the main risk of revenue concentration in Livmarli.

Among Mirum’s recent updates, the completion of enrollment in the Phase 2b VISTAS study of Volixibat in primary sclerosing cholangitis stands out in this context. As VISTAS moves toward topline data, its outcome will sit alongside Livmarli’s label expansion efforts in shaping how investors view Mirum’s path from a single product centric story to a broader rare‑liver franchise.

However, investors should be aware that growing dependence on Livmarli in the face of evolving competitive therapies and pricing scrutiny...

Read the full narrative on Mirum Pharmaceuticals (it's free!)

Mirum Pharmaceuticals' narrative projects $794.3 million revenue and $102.1 million earnings by 2028.

Uncover how Mirum Pharmaceuticals' forecasts yield a $103.10 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community place Mirum’s fair value between US$34.86 and US$291.87, underscoring how far apart individual views can be. When you weigh those opinions against Mirum’s reliance on Livmarli and pending Volixibat trial results, it becomes clear why many investors look at several perspectives before forming a view on the company’s prospects.

Explore 5 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth less than half the current price!

Build Your Own Mirum Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 39 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com